Global Liquid Biopsy Markets Strategies and Forecasts 2015-2020 - Blood Tests replace Surgical Biopsies to create a new multibillion dollar market opportunity.
DUBLIN, Sept. 14, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/j245hc/liquid_biopsy) has announced the addition of the "Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2015 to 2020" report to their offering.
Blood Tests replace Surgical Biopsies to create a new multibillion dollar market opportunity.....
The Screening Test opportunity is explored
New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The biggest numbers we've seen in the Clinical Diagnostics space. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
This independent research gives you the facts to speak with authority.
Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers.
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
3. Market Trends
4. Liquid Biopsy Recent Developments
5. Country Market Sizes - North America
6. Country Markets - Europe
7. Country Markets - Asia Pacific
8. Country Markets - Latin America, Africa & The Middle East
9. Global Market Summary
10. Potential Market Opportunity Sizes
Companies Mentioned
- ApoCell
- AstraZeneca Initiates
- BioFluidica
- Biocept
- Biodesix
- Cynvenio
- CytoTrack
- Cytolumina Technologies Corp
- Diagnologix LLC
- EGFR Monitoring
- EKF Diagnostics
- Epic Sciences
- European Consortium
- Exosome Sciences
- Fluidigm Corp
- Horizon Discovery
- Illumina
- Inivata
- Inivata Raises
- Janssen Diagnostics
- LGC
- Merck Serono
- Qiagen
- RainDance Technologies
- Rarecells SAS
- Roche
- Rosetta Genomics
- SRI International
- SWOG
- Silicon Biosystems
- Sysmex Inostics
- TGen
- Tokai
- Trovagene
For more information visit http://www.researchandmarkets.com/research/j245hc/liquid_biopsy
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article